CMS certification 463301
Primary Children's Hospital
100 North Mario Capecchi Drive, Salt Lake City, UT 84113
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
619 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 98 |
| Nurse Practitioner | 56 |
| Family | 34 |
| Neonatal | 30 |
| Physician Assistant | 29 |
| Physical Therapist | 28 |
| Neonatal, Critical Care | 22 |
| Occupational Therapist | 22 |
| Pediatric Cardiology | 19 |
| Nutrition, Pediatric | 18 |
| Speech-Language Pathologist | 18 |
| Pediatric Hematology-Oncology | 16 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $291,803
- 2020 $411,675
- 2021 $63,844
- 2022 $11,058
- 2023 $336,986
- 2024 $1.1M
- 2025 $1.4M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Speaking, teaching and other services | $12,000 | 1 |
| Grants | $10,000 | 1 |
| Space rental and facility fees | $5,000 | 1 |
| Medical devices and supplies on long-term loan | $4,727 | 10 |
| Debt forgiveness | $766 | 2 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Janssen Scientific Affairs, LLC | $393,282 | 4 |
| Ethicon Inc. | $311,463 | 8 |
| Janssen Research & Development, LLC | $205,462 | 7 |
| Fresenius Medical Care Renal Therapies Group, LLC. | $138,813 | 8 |
| Fresenius USA Marketing, Inc. | $120,521 | 4 |
| Genentech, Inc. | $82,413 | 24 |
| Biosense Webster, Inc. | $39,129 | 3 |
| Radiometer America, INC | $34,344 | 2 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| Impact of a system-wide Transplant Assessment Program on access to Stem Cell Transplant and effect on disease outcomes within patients Janssen Scientific Affairs, LLC | $393,282 |
| Safety of Regional Citrate Anticoagulation (SARCA Study) (SARCA) Fresenius Medical Care Renal Therapies Group, LLC. · NCT05339139 | $259,334 |
| eVTE: Prospective validation of a novel intervention to deploy extended duration thromboprophylaxis selectively among at-risk discharging hospitalize… Janssen Research & Development, LLC | $194,998 |
| A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of ETHIZIA versus SURGICEL Original in Controlling M… Ethicon Inc. | $176,458 |
| A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of ETHIZIA versus SURGICEL Original in Controlling M… Ethicon Inc. | $135,005 |
| A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC Genentech, Inc. | $46,285 |
| Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Ablation (PFA) System with OMNYPU… Biosense Webster, Inc. | $39,129 |
| Ph 2 Randomized POC Study of PCV in 1L Melanoma Genentech, Inc. | $35,741 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Primary Children's Hospital
Does Primary Children's Hospital have an emergency room?
Yes. CMS lists emergency services at Primary Children's Hospital.
Does Primary Children's Hospital receive money from drug and device companies?
Drug and device makers reported $1.4M in payments to Primary Children's Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.